Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11108303 | 0.86 | CHRM5 (0.43) | CHRM5CHRM3OPRD1SIGMAR1CYP1A2 | |
| SCHEMBL17141355 | 0.81 | ATM (0.39) | SIGMAR1CYP1A2MEN1KMT2A | |
| SCHEMBL17141389 | 0.81 | ATM (0.39) | SIGMAR1CYP1A2MEN1KMT2A | |
| SCHEMBL730166 | 0.78 | TSHR (0.47) | CHRM5CHRM3OPRD1SIGMAR1CYP1A2 | |
| SCHEMBL733022 | 0.78 | CHRM5 (0.40) | CHRM5CHRM3OPRD1SIGMAR1CYP1A2 | |
| SCHEMBL6396274 | 0.76 | SMN1; SMN2 (0.47) | KMT2A | |
| SCHEMBL9331350 | 0.75 | CHRM5 (0.38) | CHRM5CHRM3OPRD1SIGMAR1CYP1A2 | |
| SCHEMBL3127868 | 0.75 | CA1 (0.41) | CHRM5CHRM3SIGMAR1CA2CA1 | |
| SCHEMBL9317068 | 0.73 | SIGMAR1 (0.37) | CHRM5CHRM3OPRD1SIGMAR1CYP1A2 | |
| SCHEMBL27154469 | 0.73 | CHRM5 (0.42) | CHRM5CHRM3SIGMAR1CYP1A2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596039-B1 | PROCESS FOR MANUFACTURING CHAIN-EXTENDED HYDROXYETHYLETHYLENEAMINES, ETHYLENEAMINES, OR MIXTURES THEREOF | NOURYON CHEMICALS INT BV (NL) | 2021-05-05 | — | — | EP | disclosed |
| US-20200131136-A1 | PROCESS FOR MANUFACTURING CHAIN-EXTENDED HYDROXYETHYLETHYLENEAMINES, ETHYLENEAMINES, OR MIXTURES THEREOF | NOURYON CHEMICALS INTERNATIONAL B.V. (NL) | 2020-04-30 | — | — | US | disclosed |
| EP-1421087-A1 | DIAZACYCLOALKANES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003016316-A1 | DIAZACYCLOALKANES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2003-02-27 | — | — | WO | disclosed |
| US-3864345-A | Process for preparing novel N-(piperazinylethyl)-carbamates | DOW CHEMICAL COMPANY, THE | 1975-02-04 | — | — | US | disclosed |
| US-3864345-A | Process for preparing novel N-(piperazinylethyl)-carbamates | DOW CHEMICAL COMPANY, THE | 1975-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131136-A1 | PROCESS FOR MANUFACTURING CHAIN-EXTENDED HYDROXYETHYLETHYLENEAMINES, ETHYLENEAMINES, OR MIXTURES THEREOF | HNMT, PNMT, HRH2 | CHRM5 205/4885CHRM3 174/4885OPRD1 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.